Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that drugs of the SGLT2i class, such as empagliflozin, canagliflozin, and dapagliflozin, have pleiotropic effects in preventin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Theranostics
Autors principals: Liu, Zhenghong, Ma, Xiaoxuan, Ilyas, Iqra, Zheng, Xueying, Luo, Sihui, Little, Peter J., Kamato, Danielle, Sahebkar, Amirhossein, Wu, Weiming, Weng, Jianping, Xu, Suowen
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2021
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7977463/
https://ncbi.nlm.nih.gov/pubmed/33754074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.54498
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars